Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Century Therapeutics, Inc.IPSC · Entity 5739 | President of R&D | March 07, 2024 | March 11, 2024 |
| Juno Therapeutics, Inc.JUNO · Entity 168572 | EVP, Research & CSO | February 07, 2017 | February 09, 2017 |
| Replimune Group, Inc.REPL · Entity 4707 | Director | April 01, 2024 | April 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Century Therapeutics, Inc.
Report date March 07, 2024 · Filed March 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,000 |
Reported balance
After 2024-03-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-03-07 · Grant · Acquired 24,000 · Balance 24,000 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.32 · Expires 2034-03-07 | Direct | 146,000 |
Reported balance
After 2024-03-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-07 · Grant · Acquired 146,000 · Balance 146,000 F2: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Irrevocable Spousal Trust for Rhonda L. Zuckerman | 536,544 |
Reported balance
Holding disclosure · report date 2024-03-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 536,544 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.
F2: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.
Juno Therapeutics, Inc.
Report date February 07, 2017 · Filed February 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 131,334 |
Reported balance
After 2017-02-07 transaction · row 1
1 source rowRow 1 · 2017-02-07 · Grant · Acquired 14,634 · Balance 131,334 F1: Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of February 7, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.76 · Expires 2027-02-06 | Direct | 68,182 |
Reported balance
After 2017-02-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-07 · Grant · Acquired 68,182 · Balance 68,182 F2: 1/48th of the shares subject to the option vests and becomes exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of February 7, 2017.
F2: 1/48th of the shares subject to the option vests and becomes exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.
Replimune Group, Inc.
Report date April 01, 2024 · Filed April 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.73 · Expires 2034-04-01 | Direct | 32,000 |
Reported balance
After 2024-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-01 · Grant · Acquired 32,000 · Balance 32,000 F1: The shares underlying this option vest entirely on April 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest entirely on April 1, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2024 Filed Apr 3, 2024 20:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001104659-24-043247 · tm2410652-6_4seq1.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2025. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 23:34 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 146,000 | $0.00 Strike: $5.32 | $0.00 |
DisclosureSEC source: 0001062993-24-006181 · form4.xml · derivative · entry 3 Levitsky Hyam · CIK 0001375792 · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,000 Underlying: Common Stock · 146,000 shares Expires 2034-03-07 F2 · derivative.exercise_date: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 23:34 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-006181 · form4.xml · nonDerivative · entry 1 Levitsky Hyam · CIK 0001375792 · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:56 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001062993-23-009200 · form4.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-04-12 F1 · derivative.exercise_date: The option vests 25% on April 12, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:03 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 25,200 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041731 · tm2311410-11_4seq1.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,200 Underlying: Common Stock · 25,200 shares Expires 2033-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2024. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 16:08 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042748 · tm2211665-14_4seq1.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2023. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:50 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0001062993-22-001687 · form4.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · President of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: The option vests 25% on January 25, 2023, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046725 · tm2112099-7_4seq1.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 16:32 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001104659-20-042502 · a4.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2021. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 17:27 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-19-019715 · a4.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2029-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2020. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 17:23 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047454 · a4.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2028-07-19 F1 · derivative.exercise_date: This option was granted on July 19, 2018 subject to the completion of the Issuer's initial public offering, which closed on July 24, 2018. 25% of the shares underlying this stock option vest on July 19, 2019 and the remainder of the shares underlying this stock option vest in 24 equal monthly installments thereafter. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:36 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantStock Option (Right to Buy) · Derivative | 68,182 | $0.00 Strike: $20.76 | $0.00 |
DisclosureSEC source: 0001209191-17-009299 · doc4.xml · derivative · entry 2 Levitsky Hyam · CIK 0001375792 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,182 Underlying: Common Stock · 68,182 shares Expires 2027-02-06 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vests and becomes exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:36 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 14,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009299 · doc4.xml · nonDerivative · entry 1 Levitsky Hyam · CIK 0001375792 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,334 F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of February 7, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.